ANTX - AN2 Therapeutics Total Debt to Capital

AN2 Therapeutics, Inc. (ANTX) management is currently revising its development plan following a pause in trials of its lead product. This daily price action on GURU.Markets reflects a debt-to-equity ratio of 0.00. There are currently no firm dates for the new tests of the antibiotic for pulmonary pathologies, although the decline in value has already been priced in. The company's revenues rely on insurance payments for the treatment of resistant infections.

This ratio determines the degree of financial autonomy by comparing total liabilities to net equity to assess the business's dependence on external borrowings. By analyzing the historical debt-to-equity ratio, an investor can identify the liquidity shortage risk for AN2 Therapeutics, Inc. (ANTX), where the high burn rate associated with antibiotic clinical trials could lead to a critical increase in leverage should drug development fail.